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1. Introduction  
The ketogenic diet (KD) is a high fat, low carbohydrate diet that has been used for 
intractable childhood epilepsy since the early 1920s. After the resurgence of the ketogenic 
diet in the mid 1990s, it has been used worldwide for the treatment of refractory pediatric 
epilepsy. Thus the ketogenic diet is an established, effective nonpharmacologic treatment for 
intractable childhood epilepsy. Over the past decade the role of the ketogenic diet in the 
treatment of intractable epilepsy has became evident from the explosion of interest and 
publications available, as well as the increased number of epilepsy centers that offer the 
ketogenic diet. However, the ketogenic diet is not yet a convenient therapy, especially 
because the customary diets of Asian countries contain substantially less fat than the 
traditional Western diets. Therefore, recent research endeavor to achieve a safer and more 
convenient dietary treatment for refractory pediatric epilepsy. 
Recent consensus of ketogenic diet by expert’s opinion provided guideline in using the diet. 
Suggested protocols, which include changes to the applicable ages, seizure types, and 
etiologies, the initiation of the diet, changes in the ratio of constituents to reduce the fat 
content, the duration of the diet, and revised formulae, such as ketogenic milk or the all-
liquid ketogenic diet, have attempted to extend the indications of the ketogenic diet and 
increase its tolerability. Physicians should also be aware of the various complications of the 
diet. Less restrictive ketogenic diet including a modified Atkins and low-glycemic-index 
diets have also been clinically tried with comparable efficacies.  
This chapter will provide practical recommendations to guide the management of the 
ketogenic diet in childhood epilepsy and give a review on the current state of ketogenic diet.  
2. Background 
Epilepsy is the most common serious neurological condition in the world, with an estimated 
prevalence of 1% of the population. Traditional epilepsy management includes 
pharmacological treatment, epilepsy surgery, and vagal nerve stimulation. Despite these 
therapies, 25% of children continue to have uncontrolled seizures. The ketogenic diet, which 
has been in use since 1921, is a treatment option for many of these children. The original 
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classical ketogenic diet is based on a ratio of fat to carbohydrate and protein, usually 3:1 or 
4:1. Protein is kept to minimum requirements for growth, and carbohydrate sources are 
mostly limited to small portions of vegetables or fruit. The classic diet is calculated using a 
ratio of the weight of fat to the sum of protein and carbohydrate. Protein is provided to meet 
dietary reference intake, which is approximately 1 g per kilogram of body weight. 
Carbohydrate completes the remaining allowance of the ratio. Although it is a “ketogenic 
diet,” one nutrient class (carbohydrates) is depleted, while providing an alternative fuel 
source for the brain with another substrate (ketones), which may be anticonvulsant.  
Ketogenic diets are categorized as either long-chain fatty acid based or medium-chain fatty 
acid based. The classical ketogenic diet uses long-chain triglycerides (LCT). Medium-chain 
triglycerides (MCT) are more ketogenic than LCTs, as octanoic and decanoic acids are more 
easily transported into the cell (Huttenlocher, 1976). Since it is more ketogenic, the MCT 
ketogenic diet (MCT-KD) allows for a lower overall fat content and subsequent greater 
inclusion of protein and carbohydrate in the daily intake (Sinha & Kossoff, 2005). Clinically, 
there does not appear to be a difference in efficacy between the MCT and the LCT diets 
(Huttenlocher et al., 1971; Schwartz et al., 1989). Patients on the MCT diet are more likely to 
experience abdominal bloating and diarrhea than those on the LCT diet, which is believed 
by some, in return, to be less palatable than the MCT diet. In addition, patients on the LCT 
diet are more prone to constipation than those consuming an MCT diet (Hartman & Vining , 
2007). Other options have been devised for using the diet in particular situations, such as in 
patients fed through a gastrostomy tube or in infants. These diets include ketogenic diet 
formulas of the Nutricia’s (MD, USA) KetoCal®, Solace Nutrition’s (MD, USA) KetoVolve® 
and Ketonia™ in South Korea. The availability of these formulas for infants, particularly 
those with gastrostomy tubes, makes palatability less of a problem in this patient population 
(Sinha & Kossoff, 2005). For infants with epileptic encephalopathy and infantile spasms, a 
short-term trial of the diet for about 6-12 months, including a 2-4 month tapering-off period, 
can be considered (Kang et al., 2011).  
The ketogenic diet is an effective treatment for medically refractory epilepsy, and is 
characterized by elevations in ketone bodies and fatty acids in both blood and brain. While a 
detailed understanding of the anticonvulsant mechanisms of action of the ketogenic diet has 
remained elusive, recent investigations have suggested that a global shift from glycolysis to 
fatty acid oxidation is necessary to achieve the desired clinical effects. Moreover, there are 
growing data indicating that the ketogenic diet – whether through ketone bodies or PUFAs 
– can exert neuroprotective actions, most likely by enhancing ATP production and 
decreasing ROS production, both of which help to preserve mitochondrial integrity. Also 
there is growing evidence that the ketogenic diet alters the fundamental biochemistry of 
neurons in a manner that not only inhibits neuronal hyperexcitability but also induces a 
protective effect (Kim do & Rho, 2008).  
3. The history of the ketogenic diet 
Fasting has been used in the treatment of epilepsy since Biblical times (Matthew 17:5-21). To 
mimic the metabolism of fasting, the ketogenic diet was introduced by modern physicians 
as a treatment for epilepsy in the 1920s (Geyelin, 1921). Wilder (Wilder, 1921) postulated 
that the antiepileptic effect of the diet was related to the production of ketones and not to 
starvation. He proposed that increasing the fat content in the diet while reducing the 
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carbohydrate would lead to reduction in seizure frequency. In the following decades, the 
use of the ketogenic diet were eclipsed as phenytoin, and then other anticonvulsants, 
became available in the late 1930s. With the development of newer antiepileptic drugs with 
improved efficacy and convenience, there was a significant decrease in the use of the 
ketogenic diet. However, the varied adverse effects of such medications should be 
considered, especially since more than 25% of epilepsy remains intractable, despite the 
development of new anticonvulsants (Kwan & Brodie, 2000). 
The diet regained widespread recognition as a viable treatment option beginning in 1992 
due to the efforts of parent advocate groups. This changed dramatically when the ketogenic 
diet received national media attention via NBC-TV's Dateline program on the treatment. This 
television program was based on the true story of Charlie, a 2-year-old boy with intractable 
generalized seizures, who presented out of desperation to Johns Hopkins Hospital for 
treatment. He was seen by Dr. Freeman and Ms. Millicent Kelly (the same dietitian who had 
worked with Dr. Livingston) and initiated on the ketogenic diet. He quickly became seizure-
free and the Charlie Foundation was formed by his father. He made videos for parents, 
physicians, and dietitians about the ketogenic diet. In addition, he directed the movie First 
Do No Harm, starring Meryl Streep, in 1997, which presented the ketogenic diet as a miracle 
cure for epilepsy. This exposure to the diet in the popular media contributed to a movement 
led by patients and their families to expand use of the treatment (Bailey et al., 2005). The 
Foundation also supported the first multicenter prospective study of the efficacy of the 
ketogenic diet (Vining et al., 1998). There has been an explosion in both the use, and 
scientific interest in the ketogenic diet. The ketogenic diet has experienced a reemergence in 
recent years and modern clinical studies have established the treatment as significantly 
effective (Freeman et al., 1998). The ketogenic diet is now available in over 45 countries 
(Kossoff & McGrogan, 2005). 
4. Efficacy and complications of the ketogenic diet 
To establish the efficacy of the ketogenic diet, this procedure requires the development of a 
blinded prospective study using a well-defined cohort and sufficient sample size (i.e., Class 
One Evidence). To date, no studies met the criteria for Class One Evidence for efficacy in the 
use of ketogenic diet in children with refractory epilepsy. The development of a blinded 
prospective trial of the ketogenic diet in children would be difficult to design (Thiele, 2003). 
Finding a placebo with similar metabolic responses to the diet both at the time of initiation 
(i.e., acidosis, lethargy, hypoglycemia) and during the maintenance phase (presence of 
ketones) that does not have antiepileptic properties would be difficult. Therefore, the diet's 
efficacy has been established primarily through large case series. Many reports on the 
efficacy of the ketogenic diet have shown similar outcomes. After 12 months on the 
ketogenic diet, about 50% of patients remained on the diet, 30%-70% of patients showed a 
reduction in seizure frequency of more than 50%, and 10%-20% were seizure-free(Kang et 
al., 2005). Recent papers (Keene, 2006) reported an overall reduction of seizure frequency 
greater than 50% in approximately one third of children initiated on the diet. The duration 
the child remained on the diet was variable, with over half the children discontinuing the 
diet between 6 months and a year after the treatment onset. Although the efficacy of the 
ketogenic diet is not maintained in all patients after they discontinue the diet, beneficial 
effects persist in most patients relative to their symptoms prior to diet initiation(Hemingway 
et al., 2001; Kang et al., 2005). Because of the variation in study designs and in the 
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description of the clinical variables (such as seizure type, electroencephalographic findings, 
duration of treatment), it was not possible to assess which child might benefit most from the 
diet (Keene, 2006). The widespread acceptance of the ketogenic diet has ended the debate 
about its efficacy. 
The ketogenic diet predisposes to nutritional deficits in energy, proteins, minerals, and 
vitamins and excess in lipids, saturated fat, and cholesterol. Use of such an unbalanced diet 
requires particular attention regarding its implementation and monitoring, particularly in 
children. Some adverse events may occur within a few days or a month of commencing the 
diet, although others may occur after several months (table 1)(Freeman et al., 2006; Kang et 
al., 2004; Lyczkowski et al., 2005). The potentially serious complications should also be 
considered. Rare, life-threatening complications, such as cardiomyopathy, serious infections, 
or aspiration pneumonia leading to respiratory distress, should be carefully monitored for 
during follow-up (Kang et al., 2004). Especially in patients with cardiac arrhythmias such as 
prolonged QT interval (Best et al., 2000), and in patients with underlying metabolic 
disorders or those taking zonisamide, topiramate, or acetazolamide (Kossoff et al., 2002; 
Takeoka et al., 2002), the use of the diet might be associated with a higher risk of adverse 
events. However, most events are transient or can be controlled with regularly scheduled 
assessments (table 2) and conservative management.  
 
Early- and late-onset Late-onset
Gastrointestinal disturbances* Growth retardation 
Dehydration† Hepatic failure 
Infectious disease‡ Exacerbation of gastro-esophageal reflux 
Sepsis Mineral deficiencies 
Lipoid aspiration pneumonia Vitamin deficiencies 
Hepatitis Osteopenia 
Acute pancreatitis Renal stone 
Biochemical disturbances Cardiomyopathy 
Abnormal lipid profiles§ Prolonged Q-T interval 
Symptomatic hypoglycemiaΠ Iron deficiency anemia 
Persistent metabolic acidosis 2nary hypocarnitinemia 
Hypoproteinemia Optic neuropathy 
Repeated hyponatremia Basal ganglia injury 
Hyperuricemia  
(*) Nausea/vomiting, diarrhea, constipation, loss of appetite. (†) A body weight reduction of over 5% of 
the baseline and marked dry skin or mucous turgor with increased urine specific gravity of over 1.020. 
(‡) Pneumonia, cystitis, nonspecific febrile illness. (§) High triglyceridemia, high cholesterolemia, low 
high density lipoproteinemina. (P) <40 mg% of blood sugar with nausea, lethargy, perspiration, 
dizziness, tachycardia and pale appearance. (Adapted from Dr. Kang HC). 
Table 1. Early- and late-onset complications of the ketogenic diet.  
5. Protocol of the classic ketogenic diet  
While the Hopkins protocol has been the basic model, the general protocol has evolved over 
time, as new advances have been made in how the diet is administered and followed (Kang 
& Kim, 2006). Prior to introducing the ketogenic diet, patients are screened by history and 
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exam (as well as supporting laboratory studies, if indicated) for metabolic disorders that 
may affect their ability to generate adequate amounts of ketones. A brief hospitalization for 
3-7 days was also recommended to give parents and children extensive instructions on how 
to calculate and prepare the diet, identify potential sources of glucose, and address other 
possible sources of error in administering the diet. On the first day of feeding, the patient is 
given 1/3 of the planned total caloric intake; on the second day, 2/3 of the total calories are 
administered, and on day 3, the full (previously calculated) caloric intake is administered. 
While on the diet, patients should also receive recommended daily intakes of vitamins and 
minerals (in sugar-free formulations), as well as calcium supplementation, as the ketogenic 
diet is not nutritionally complete. During the diet's initiation, blood glucose, urine ketones, 
and vital signs are monitorred. The outpatient phase of the ketogenic diet consists of routine 
clinic visits (3, 6, 12, 18, and 24 months after starting the diet) with the staff and laboratory 
measurements, along with frequent contact with the nutritionist (table 2).  
 
Pre-diet 
Metabolic workups* (lactate, urine organic acid and plasma amino acid assay, plasma 
acylcarnitine profiles) urine ALA and PBG† 
0,1,2,3,4 days and monthly 
Blood ketone, blood sugar (every 12 hours for 4 days) 
0,3 days and 1,3,6,12,18,24 months 
CBC with platelets, BUN/creatinine, liver profiles‡, electrolytes with tCO2, 
calcium/phosphorus/alkaline phosphatase, magnesium, uric acid, lipid profiles§, 
urinalysis, PT/PTT, urine ca/urine creatinine 
0,6,12,24 months 
Blood AED levels, abdominal ultrasonography, echocardiography 
plain X-ray on wrist, if needed, bone densitometry, bone enzyme profilesΠ 
Intermittently 
Urine ketone¶ 
ALA = d-aminolevulinic acid; PBG = porphobilinogen; CBC = complete blood count; BUN = blood urea 
nitrogen; PT = prothrombin time; PTT = partial thromboplastin time; AED = antiepileptic drug. (*) In 
children with associated developmental delay of unknown etiology, hypotonia, exercise intolerance, 
cyclic vomiting, fatigability, hepatomegaly, cardiomyopathy, pigmentary retinitis, hypoacusia, 
metabolic acidosis, hypoglycemia, hyperammonemia or unexpected ketonuria. (†) Especially in 
nationalities that have high incidence of acute intermittent porphyria. (‡) Total protein/albumin, total 
bilirubin, aspartate aminotransferase and alanine aminotransferase. (§) Cholesterol, high density 
lipoprotein-cholesterol, triglyceride. (P) Parathyroid hormone, 25(OH) vitamin D3, 1.25(OH)2 
vitaminD3, osteocalcin. (¶) Recommend measurement of urine ketones at home, especially when 
seizures occur or seizure frequencies increase. (Adapted and revised from Dr. Kang HC) 
Table 2. Scheduled assessments to screen medical contraindications and evaluate 
complications of the classic ketogenic diet.  
There is the need for standardized protocols and management recommendations for both 
clinical and research use of the diet, because the ketogenic diet is provided differently 
throughout the world, with occasionally significant variations in its administration. In 
December 2006, the Charlie Foundation commissioned an international committee of 
neurologists and dietitians with expertise in the ketogenic diet. The charge of this consensus 
group was to provide practical recommendations to guide management of the ketogenic 
diet (Kossoff et al., 2009). Recommendations are as follows: 
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Patient selection 
The ketogenic diet should be strongly considered in a child who has failed two to three 
anticonvulsant therapies, regardless of age or gender, and particularly in those with 
symptomatic generalized epilepsies. The ketogenic diet yielded a good response in patients 
with an immature cerebral cortex due to developmental malformation (Jung et al., 2008b). It 
can be considered the treatment of choice for two distinct disorders of the brain metabolism, 
i.e. the GLUT-1 deficiency syndrome and PDHD. In particular epilepsy syndromes, such as 
the Dravet syndrome, infantile spasms, myoclonic-astatic epilepsy, and tuberous sclerosis 
complex, the ketogenic diet could be offered earlier. Before starting the ketogenic diet, 
inborn errors of metabolism that could lead to a severe metabolic crisis should be ruled out. 
For example, defects in fatty acid oxidation generally are contraindications to starting the 
ketogenic diet. Absolute contraindications to the ketogenic diet include pyruvate 
carboxylase deficiency and porphyria.  
Medications and the ketogenic diet  
There is little evidence of any consistent positive interactions between the ketogenic diet and 
anticonvulsants. The ketogenic diet may work well in combination with VNS. Conversely, 
the ketogenic diet is not negatively affected in regards to efficacy or side effects by any 
particular anticonvulsant. Medications can often be reduced within the first few months if 
the ketogenic diet is successful, although caution is advised especially when reducing 
phenobarbital and benzodiazepines. 
Maintenance of children receiving the ketogenic diet 
Ongoing clinic visits at least every 3 months for the first year, with ready access to 
experienced advice, are important for the successful management of children receiving the 
ketogenic diet. More frequent visits may be necessary for infants and other patients at high 
risk for nutritional deficiency. All children should be seen by experienced pediatric 
neurologists and dietitians and should have a nutritional assessment, laboratory evaluation, 
and discussion regarding ketogenic diet and anticonvulsant discontinuation decisions. 
Ketogenic diet discontinuation 
Consideration should be given to discontinue the ketogenic diet after 3 months if 
unsuccessful, or after 2 years if completely successful. However, longer diet durations are 
usually necessary for GLUT-1 and PDHD and may be perfectly appropriate, based on 
individual responses for intractable epilepsy. Prior to diet discontinuation in seizure-free 
children, a routine EEG and review of clinical data should be performed to counsel families 
regarding recurrence risk, which is 20% overall. Children with an epileptiform EEG, 
abnormal MRI, and tuberous sclerosis complex are at higher risk. During discontinuation, 
the group generally recommends a gradual wean over 2–3 months, as outlined above, 
unless an urgent discontinuation of the diet is indicated. 
6. Newer versions of the diet  
In Asia, even now, the ketogenic diet is still not convenient to use, especially because the 
customary diets of Asian countries contain substantially less fat than traditional Western 
diets. Moreover, in adolescents, an unpalatable diet may cause resistance and poor 
compliance and a lower ability to extract ketones from the blood into the brain can be a 
barrier to its effectiveness (Williamson, 1985). In addition, there are various complications 
associated with the diet and they should be carefully considered. Therefore, we require an 
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alternative diet therapy that is safer and more convenient while maintainging efficacy. In the 
last decade, variations to the classical ketogenic diet have been utilized. Recently less 
restrictive ketogenic diet, including a modified Atkins diet and low-glycemic-index 
treatment, has been suggested to replace the conventional ketogenic diet (Kossoff et al., 
2006; Pfeifer & Thiele, 2005). Modified atkins diet (grams of fat: protein and carbohydrate, 
1:1 ratio) has several advantages over the traditional ketogenic diet, most notably no 
restriction on protein, calories, or fluids. This “Modified Atkins Diet” restricts only 
carbohydrates to 10 g/day (15 g/day in adults) while encouraging high fat foods. The 
antiepileptic effects of both fasting and the ketogenic diet have been associated with 
decreased blood glucose and increased blood ketone levels (Owen et al., 1967); however, 
recent research indicates that ketosis alone cannot account for the anticonvulsant effects of 
the ketogenic diet (Greene et al., 2003); it suggests that regulation of blood glucose may be at 
least partly responsible for these effects. The glycemic index describes the tendency of foods 
to elevate blood glucose (Jenkins et al., 1981). The glycemic index is calculated from the 
incremental area under the blood glucose curve after feeding, indexed to ingested 
glucose = 100. Foods with high glycemic index (e.g., most refined carbohydrates) produce 
substantial increases in blood glucose and insulin levels, whereas foods with a low glycemic 
index (e.g., meat, dairy, some fruits, some vegetables, and some unprocessed whole-grain 
foods) induce lower postprandial plasma glucose and insulin profiles. By limiting the 
quantity of carbohydrates consumed and by restricting sources of carbohydrates to low-
glycemic index foods, the low glycemic index treatment (LGIT) is designed to prevent 
dramatic postprandial increases in the blood glucose (Pfeifer & Thiele, 2005). The low 
glycemic index treatment, compared to the ketogenic diet, allows for a more liberal total 
carbohydrate intake but restricts foods to those that produce relatively little elevation in the 
blood glucose (i.e. glycemic index <50). In conclusion, modification of the ketogenic diet 
with higher carbohydrate/protein and lower fat than the classic ketogenic diet, such as the 
modified Atkins diet or the low-glycemic-index treatment, can be used with similar efficacy 
and better tolerability (Carrette et al., 2008; Ito et al., 2008; Kang et al., 2007; Kossoff et al., 
2003; Kossoff et al., 2006; Kossoff et al., 2008; Kossoff et al., 2007; Muzykewicz et al., 2009).  
7. How to provide a successful ketogenic diet  
As current thinking focuses on making the ketogenic diet safer and more palatable, the 
original protocol has been modified and has evolved to achieve increased efficacy and 
tolerability (Kang & Kim, 2006). Improving and maintaining efficacy is a major goal in the use 
of the ketogenic diet. Comprehensive dietary education and an easy calculation method, using 
a software program based on accurate food composition analysis, are important to use the 
ketogenic diet in an optimal fashion. The calculation of a single meal can be tedious, and hence 
the possibility for errors is significant. Computer applications for calculating ketogenic diet, 
such as KetoCalculator (Zupec-Kania, 2008), are available and can save time and minimize 
errors. The presence of well trained dietitians is critical and they should instruct caregivers in 
both dietary calculation and food composition. The dietitian provides nutrition management 
and technical manipulation of the diet in order to optimize the seizure control. The dietitian is 
frequently communication with both the caregivers and the ketogenic diet team, and this 
necessitates his/her role as coordinator of the ketogenic diet program. Dietary education also 
plays an important role in increasing the efficacy of the ketogenic diet. Key members of the 
team managing the patient include physicians, nutritionists familiar with the diet, nursing 
staff, and, most importantly, patients and their families. Families should be encouraged to 
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participate in support groups to share information and build strong bonds; this, in turn, will 
increase the maintenance rate of the diet.  
To improve the antiepileptic efficacy of the ketogenic diet, the maintenance of consistent 
and strong ketosis is important. Furthermore, the lipid:nonlipid ratio affects the efficacy, as 
seen in many animal studies and one clinical study (Seo et al., 2007). When a child on the 
ketogenic diet does not show a significant reduction in seizure frequency, physicians should 
consider every possible way in which ketosis may be breached. It is important to maintain 
an accurate lipid:nonlipid ratio for each of the patient's meals and to avoid extra 
carbohydrate consumption derived from prescribed drugs or miscalculation.  
Improving tolerability is the other major arm for the successful maintenance of the diet. 
Although the Johns Hopkins protocol used for the classic ketogenic diet recommends an 
initial fasting period, a nonfasting protocol provides better tolerance in the initial period of 
the diet and avoids dehydration from fluid restriction (Bergqvist et al., 2005; Kim et al., 
2004). It can also decrease the incidence of early complications, such as acute renal failure, 
elevation of blood urea nitrogen, and electrolyte imbalance. The nonfasting ketogenic diet 
has similar antiepileptic efficacy to the conventional fasting ketogenic diet with the 
additional advantage of fewer days of hospitalization. The careful monitoring of 
complications and their prevention and management are also valuable ways to improve 
patient's tolerability during the diet's maintenance. Gastrointestinal symptoms, including 
nausea, vomiting, diarrhea, and/or constipation, which are common early complications, 
may cause both the parents and patients to consider giving up the diet. Temporary use of 
antiacids or antiemetics can help to relieve the symptoms (Jung et al., 2008a). Psychological 
support is also critical for families, as is education about complications and their prevention 
and management. To ensure successful maintenance, care-givers should have a positive 
attitude about the diet. The positive attitudes of doctors and parents seem to be the most 
important supporting factor in maintaining the diet. Although the typical ratio of fats to 
carbohydrates and protein (in terms of grams) is 4:1, lower ratios are used successfully in 
other parts of the world, such as Asia, where rice is a major dietary staple (Kossoff & 
McGrogan, 2005). Moreover, breaking with tradition and convincing the physicians and 
their patients are the most important factors to introduce the diet in Asian countries(Seo & 
Kim, 2008).  
8. Conclusion  
The ketogenic diet is a useful therapy for patients with intractable epilepsy, including some 
of the catastrophic epilepsies in infancy and childhood. This chapter is a review of previous 
and current papers regarding the proposed practical use of the ketogenic diet in epileptic 
children. The diet’s strictness, lack of palatability, and side effects limit its use and adversely 
affect both patients’ compliance and clinical efficacy. Careful planning and monitoring from 
a committed and experienced medical team will help ensure a successful ketogenic diet 
program. We should continue our endeavors to develop a safer and more convenient diet 
therapy that can be extended to more patients with refractory epilepsy.  
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Epilepsy is a neurological condition that accompanies mankind probably since its inception. About 400 years
before Christ, the disease was already known by Hippocrates, who wrote the book â€œOn The Sacred
Diseaseâ€ ​. Classically, epilepsy has been defined as a chronic condition characterized by an enduring
propensity to generate seizures, which are paroxysmal occurring episodes of abnormal excessive or
synchronous neuronal activity in the brain. Out of all brain disorders, epilepsy is the one that offers a unique
opportunity to understand normal brain functions as derived from excessive dysfunction of neuronal circuits,
because the symptoms of epileptic seizures are not the result of usual loss of function that accompanies many
disease that affect the brain. I am therefore extremely honoured to present this book. The 15 very interesting
chapters of the book cover various fields in epileptology â€“ they encompass the etiology and pathogenesis of
the disease, clinical presentation with special attention to the epileptic syndromes of childhood, principles of
medical management, surgical approaches, as well as social aspects of the disease.
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